Unbound MEDLINE

Multi-pronged inhibition of airway hyper-responsiveness and inflammation by lipoxin A(4). Nature medicine. [Nat Med] Journal article

 
TitleMulti-pronged inhibition of airway hyper-responsiveness and inflammation by lipoxin A(4).
Author(s)Levy BD, De Sanctis GT, Devchand PR, Kim E, Ackerman K, Schmidt BA, Szczeklik W, Drazen JM, Serhan CN 
InstitutionCenter for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
SourceNat Med 2002 Sep; 8(9):1018-23.
MeSHAnimals
Asthma
Bronchial Hyperreactivity
Bronchitis
Chemokines, CC
Eosinophils
Hydroxyeicosatetraenoic Acids
Interleukin-13
Interleukin-5
Leukotrienes
Lipoxins
Male
Methacholine Chloride
Mice
Mice, Inbred BALB C
Mice, Transgenic
Prostaglandins
Receptors, Cell Surface
Receptors, Formyl Peptide
Receptors, Lipoxin
Research Support, U.S. Gov't, P.H.S.
AbstractThe prevalence of asthma continues to increase and its optimal treatment remains a challenge. Here, we investigated the actions of lipoxin A(4) (LXA(4)) and its leukocyte receptor in pulmonary inflammation using a murine model of asthma. Allergen challenge initiated airway biosynthesis of LXA(4) and increased expression of its receptor. Administration of a stable analog of LXA(4) blocked both airway hyper-responsiveness and pulmonary inflammation, as shown by decreased leukocytes and mediators, including interleukin-5, interleukin-13, eotaxin, prostanoids and cysteinyl leukotrienes. Moreover, transgenic expression of human LXA(4) receptors in murine leukocytes led to significant inhibition of pulmonary inflammation and eicosanoid-initiated eosinophil tissue infiltration. Inhibition of airway hyper-responsiveness and allergic airway inflammation with a stable LXA(4) analog highlights a unique counter-regulatory profile for the LXA(4) system and its leukocyte receptor in airway responses. Moreover, our findings suggest that lipoxin and related pathways offer novel multi-pronged therapeutic approaches for human asthma.
Languageeng
Pub Type(s)Journal Article
PubMed ID12172542
  
Advertise on this site.